<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507338</url>
  </required_header>
  <id_info>
    <org_study_id>ARC1779-003</org_study_id>
    <nct_id>NCT00507338</nct_id>
  </id_info>
  <brief_title>Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI</brief_title>
  <acronym>vITAL-1</acronym>
  <official_title>A Phase 2 Study of an Aptameric Von Willebrand Factor Antagonist, ARC1779, in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Archemix Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Archemix Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ARC1779 is a novel drug being tested in patients undergoing angioplasty and stenting as their
      primary treatment for heart attack.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjunctive anti-thrombotic therapy for PCI of AMI may be improved by incorporation of a novel
      anti-platelet therapeutic principle, von Willebrand Factor antagonism. ARC1779 is a
      therapeutic oligonucleotide (&quot;aptamer&quot;) which blocks the binding of the A1 domain of vWF to
      the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and
      aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture.
      This study is intended to provide dose-ranging and clinical proof of concept for ARC1779 in a
      primary PCI population.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adequacy of reperfusion</measure>
    <time_frame>48 hours post-PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>PCI to hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>ARC1779 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC1779 mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC1779 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>abciximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>labeled regimen for primary PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>early PCI for NSTEMI; primary PCI for STEMI</description>
    <arm_group_label>ARC1779 low dose</arm_group_label>
    <arm_group_label>ARC1779 mid dose</arm_group_label>
    <arm_group_label>ARC1779 high dose</arm_group_label>
    <arm_group_label>abciximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  troponin-positive NSTEMI, with diagnostic symptoms and/or ECG abnormalities present
             within the preceding 24 hours, and a planned &quot;early invasive&quot; management strategy

          -  STEMI, with planned primary PCI

        Exclusion Criteria:

          -  History of bleeding diathesis or evidence of active abnormal bleeding within the
             previous 30 days

          -  Received treatment with fibrinolytic or GPIIb/IIIa antagonist drugs within the
             preceding 72 hours

          -  Received anticoagulant therapy with a low molecular weight heparin within the
             preceding 8 hours

          -  Severe hypertension (systolic blood pressure &gt;200 mmHg or diastolic blood pressure
             &gt;110 mmHg) not adequately controlled on antihypertensive therapy

          -  Major surgery or trauma within the preceding 6 weeks

          -  History of stroke within 30 days or any history of hemorrhagic stroke

          -  End-stage renal disease (ESRD) with dependency on renal dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gibson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard Medical School, Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franz-Josef Neumann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz-Zentrum Bad Krozingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Archemix Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Russia</state>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2007</study_first_submitted>
  <study_first_submitted_qc>July 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2007</study_first_posted>
  <last_update_submitted>January 8, 2009</last_update_submitted>
  <last_update_submitted_qc>January 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>James Gilbert, MD/Chief Medical Officer</name_title>
    <organization>Archemix, Corp.</organization>
  </responsible_party>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

